

## Initiatives toward Patient Centricity

Our Group's Purpose is to contribute to the enrichment of quality of life around the world, and core to all of our activities is our "Passion for Innovation. Compassion for Patients.®" as reflected in our corporate slogan.

Our commitment to support patients to find hope in their treatment drives all of our corporate activities. We are engaged in our activities with the belief that innovation will come from trials and errors and the continuous search for new drugs.

To make innovation more meaningful, we will further foster a patient centric mindset throughout the entire Group by continually engaging with patients and listening to their experiences, challenges, and perspectives.

We will strengthen our efforts to move toward patient centricity throughout our entire value chain.



<sup>\*1</sup> Real world data  
<sup>\*2</sup> Interstitial lung disease

## COMPASS (Compassion for Patients Strategy), a strategy for patient-oriented drug discovery

We launched COMPASS in 2014 within the R&D Division as an initiative to drive progress in implementing "Patient-Oriented Drug Discovery." We are working to contribute to patients realizing "life with a smile" around the world, based on Daiichi Sankyo's corporate slogan, "Compassion for Patients."

We undertake two main activities in Japan under the COMPASS strategy. The first is an exchange program that enables patients and healthcare professionals, and our employees to get to know and understand each other through dialogue, with the aim of improving the quality of drug discovery. The second activity involves visits of our employees to medical facilities to understand the needs and actual circumstances of diseases and treatments, which provides an opportunity for them to reaffirm their roles and responsibilities as a member of a pharmaceutical company.

When interacting with patients, it goes without saying that we must comply

[Click here for more information.](#)

[https://www.daiichisankyo.com/our\\_stories/detail/index\\_4170.html](https://www.daiichisankyo.com/our_stories/detail/index_4170.html)

with laws and regulations such as advertising regulations and personal information protection, but we have come to realize that there are issues we need to address that go beyond just complying with laws and regulations to build a relationship of mutual trust. Accordingly, we prepared a guidebook in collaboration with Takeda Pharmaceutical Co., Ltd., which shares the expertise and experience that both companies have accumulated, and provides guidelines for the collaboration with patients groups. We will use this guidebook to promote collaboration with patients in cooperation with other pharmaceutical companies.

### Thoughts behind COMPASS

A patient once told us, "We don't live for treatment, we live to do what we want to do." We at Daiichi Sankyo would like to think together with not only our employees but also patients, their families, and medical professionals about what we can all do to help patients to realize "life with a smile" despite their illness.

## Patient Advocacy - the value patient voices add to drug development

The pharmaceutical industry has moved away from advocacy simply meaning the transmittal of information about diseases and available treatments to patients. We are moving to an era of close collaboration between the company and the patient community where patient voices have an increasing impact on everything from research and drug development to treatment access. They are influential from the conception of a compound all the way to the marketplace and beyond.

### Experts in their own diseases

By listening to patients, who live day and night with their disease, the company might be able to offer alternatives within the study protocol, perhaps allowing a patient's local physician to draw the blood needed for the study or have studies that are conducted closer to where patients live.

### Listen to patients' voice

Through advocacy, we engage with patient groups in a number of ways, including one-on-one discussions, advisory boards and patient events.

[Click here for more information.](#)

[https://www.daiichisankyo.com/our\\_stories/detail/index\\_4242.html](https://www.daiichisankyo.com/our_stories/detail/index_4242.html)


### Closing the knowledge gap

We are working with the original authors of scientific peer reviewed articles to write them in lay terms, making access to science available for cancer patients and their caregivers in Europe and the United States.

### A global commitment

We established a Patient Focused Forum, a network of advocates which includes Daiichi Sankyo representatives from the many countries where the company has a presence. We will deepen our relationships with various patient groups around the world to understand the true needs of patients.

*The patient voice is stronger than ever, and patients have much to say about their expected quality of life and survival aspirations.*



Gissou DeCotiis  
Global Oncology Medical Affairs,  
Global Head of Advocacy &  
Strategic Relations

## Patient Journey Card

Our passion and compassion are what drive us every day, regardless of our roles. To have compassion, we must understand our patients' experiences, challenges and perspectives. To help create this connection, we created sets of Patient Journey Cards\* and provided them to certain employees, each card featuring a glimpse into a real patient story. We encourage our employees to select a card each morning and keep it with them during the day as a reminder of the meaning of what we do.



\*All individuals featured on our Journey cards are real patients who agreed to share their stories with us.

## Clinical Trials



### Providing access to clinical trial information

We disclose our clinical trials on our Clinical Trial Information Disclosure website and set up a contact for clinical trials so that patients can easily access to the clinical trial information they are seeking. In addition, we publish clinical trial results summaries in plain language for patients who have participated in our clinical trials.

Click here for more information. [https://www.daiichisankyo.com/rd/clinical\\_trials/list/](https://www.daiichisankyo.com/rd/clinical_trials/list/)

### Reducing the burden on patients

In order to reduce the burden on patients participating in clinical trials and to help them understand the trial more accurately, we have introduced patient-reported outcomes (ePRO) and video explanations of consent documents (eConsent) by using digital technologies in several clinical trials. Such new technologies are also working to reduce the number of visits and ensure sufficient time for patients to understand the clinical trial. In addition, we are taking on new initiatives to make it more comfortable for patients to participate in clinical trials, such as reflecting the opinions and thoughts of patients in the clinical trial-related materials we provide.

### Delivering innovative new drugs faster

With the aim of delivering new drugs as quickly as possible, we pushed forward with clinical trials even during the pandemic, and introduced a "Direct to Patients" system that enables patients to receive or be administered investigational drugs at home or at a nearby hospital without having to visit the clinical trial site. In this way, we ensured that patients can continue to participate in clinical trials even amid the COVID-19 pandemic.

### Expanding access to investigational drugs

In countries and regions where our drugs are not yet approved, we provide certain investigational drugs through Expanded Access Program or similar early access programs to eligible patients with a serious or life-threatening disease or condition, for which all currently available treatment options have been exhausted and enrollment into a clinical trial is not possible.

For example, in the treatment program that ensures the early delivery of *Enhertu*<sup>®</sup> to patients in countries and regions where *Enhertu* is not yet approved, we established a special risk management system to ensure patient safety.



## Drug Formulation

### Development of patient-friendly dosage forms

With the determination to support the safety and security of patients with drugs that are easy to take and use, we continue to develop patient-friendly dosage forms, making full use of the drug formulation technologies we have cultivated over the years. To date, we have developed and launched orally disintegrating tablets for anticoagulants and nebulizer formulations of anti-influenza agents as dosage forms that are easy for patients to take. We have also improved convenience by launching generic products with innovations in drug formulation and packaging. At the same time, we are pursuing continuous medication support for patients, as well as safety and security for healthcare professionals and caregivers.

## Clinical Safety & Pharmacovigilance

### Providing safety information in a more understandable and accessible manner

With the aim of supporting the safety and relief of patients, we are working to create and provide materials related to safety information, reflecting the needs of patients identified through healthcare professionals. For example, in the US, we are updating and improving the Patient wallet card/Patient brochure\*<sup>1</sup> in a timely manner. Furthermore, in Japan, we are working to improve access to information, for example, by posting a list of Drug Information Sheets on our website. We are also collecting and analyzing information on safety and efficacy of our products in the real world after product launch, and publishing the results in articles and at academic conferences. As above examples, we are working on activities that are appropriate to the specific circumstances in each country.

\*<sup>1</sup> Materials designed to provide patients with product-related information in an easy-to-understand manner.



## Digital Therapeutics (DTx\*<sup>2</sup>)

### Providing DTx

We are working to develop DTx with the will to provide personalized healthcare solutions that closely align with the life journey of each patient and individual. We are continuously surveying the challenges and needs of patients to reflect them in our DTx development, and are aiming to use DTx to fill in the gaps in patient treatment, including when they are at home, and to help them improve their physical, mental, and social well-being. As a first step, we are working to develop DTx in the field of oncology toward obtaining medical device approvals and insurance coverage as early as possible (clinical research is scheduled to begin in FY2022).

\*<sup>2</sup> We define DTx as software solutions that have evidence-based therapeutic capabilities in providing medical interventions directly to patients to prevent, manage, or treat a medical disorder or disease, and are developed to be reviewed and approved by regulatory bodies as a medical device (manufacturing and marketing approval).



## Social Contribution Activities

### Supporting cancer patients and their families

With the aim of facing cancer together with the entire community and supporting cancer patients and their families, we participate in Relay for Life Japan (RFLJ), an initiative to get closer to patients and support their fight against cancer. In FY2021, over 100 Daiichi Sankyo Group employees and their families participated online in RFLJ Ochanomizu, walking around the country and making donations based on the number of steps taken.